PPT-Safety of Tenofovir

Alafenamide in Renal Impairment A Pozniak 1 J Arribas 2 SK Gupta 3 FA Post 4 A Avihingsanon 5 G Crofoot 6 K Lichtenstein 7 M Ramgopal 8 P Chetchotisakd 9 MW Fordyce. Safety Break Safety Break Safety Break Safety Break Safety Break Safety Break Lap Swim (2) Open Swim (2) Lap Swim (2) 10:00am-4:25pm Open Swim (2) 12:10pm-2:30pm Safety Break Safety Break Safety Bre An HIV pre-exposure prophylaxis trial in Thailand: . participant adherence and study results . National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of HIV/AIDS Prevention. A collaborative project involving: The Bangkok Metropolitan Administration, the. based . PrEP. technologies in women : . what do we currently know?. Linda-Gail Bekker . The Desmond Tutu HIV Centre. University of Cape Town.. Expanding HIV Prevention Options for Women.. The need for a female initiated, managed and controlled prevention methodology.. Jennifer Hoy. , MBBS. Professor of Medicine. Director, HIV Medicine. The Alfred Hospital. FINAL: 07-20-12. Phillip, Aged 67 Years. HIV infection diagnosed on screening for HBV treatment trial in 1995. M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 3rd Quarter. October-December 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Treatment-naïve Patients . Clinical Instructor, Harvard Medical School. Director of Research, CRI New England. Vice Chair, INSIGHT Scientific Steering Committee. Boston, USA . Calvin Cohen, MD, MSc. Drew Lambert, . PharmD. lambertd@husson.edu. Husson University School of Pharmacy. 1. PollEverywhere. - Text . DREWLAMBERT221 to 22333 to join. You . can respond at . PollEv.com/drewlambert221. I have no conflicts of interest.. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 1. st. Quarter. APRIL-JUNE 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Tenofovir. . Alafenamide. . vs. . Tenofovir. . Disoproxil. . Fumarate. Combined Safety Results of . Studies GS-US-292-0104 and GS-US-292-0111. Paul Sax. 1. , Michael Saag. 2. , Michael Yin. 3. , Frank Post. STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg.